Latest news with #VSD
Yahoo
27-05-2025
- Business
- Yahoo
Revenue, Outlook, Value, Industry, Forecast, Analysis, Growth, Share, Companies, Size & Trends 2021-2030
The Australian Variable Speed Drive (VSD) market is set to grow, driven by increasing demand for energy-efficient solutions in sectors like manufacturing, mining, and HVAC from 2021 to 2024. Government initiatives focusing on sustainability, such as support from ARENA and the Energy Efficiency Council, propelled the adoption of VSDs, resulting in a 5.2% CAGR revenue growth projected from 2025 to 2031. Key segments like low-voltage and medium-voltage VSDs are anticipated to lead the market, supported by the growing emphasis on automation and net-zero emissions goals. Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Australia VSD Market | Revenue, Outlook, Value, Industry, Forecast, Analysis, Growth, Share, Companies, Size & Trends: Market Forecast By Type, By Voltage, By End-UserAnd Competitive Landscape" has been added to offering. Research indicates that the Australian VSD market is anticipated to grow at a CAGR of 5.2% in revenue and 3.7% in volume from 2025 to 2031. The Australian Variable Speed Drives (VSD) market has witnessed substantial growth from 2021 to 2024, driven largely by the increasing demand for energy-efficient solutions and significant advancements in industrial automation across key sectors such as manufacturing, mining, and HVAC. Government initiatives aimed at enhancing sustainability, including programs implemented by the Energy Efficiency Council and funding through the Australian Renewable Energy Agency (ARENA), have effectively facilitated the adoption of VSD technologies. This growth trajectory is further supported by Australia's robust push for improved energy management practices and a concerted effort to minimize carbon emissions during this period. The forecast is bolstered by several factors, including increased industrial automation, rising demand for energy-efficient technologies, and sustained government support targeting net-zero emissions by 2050. With a goal of reaching 43% emissions reduction relative to 2005 levels, and aiming for an 82% national renewable electricity target by 2030, Australia is incentivizing industries to adopt energy-efficient solutions like VSDs extensively. ARENA and the Clean Energy Finance Corporation (CEFC) are also actively funding energy-efficient projects, providing significant support for motor systems and automation upgrades. The Australian Government's May 2024 Federal Budget highlights a substantial allocation of $22.7 billion to support areas including renewable hydrogen, critical minerals processing, green metals, low-carbon liquid fuels, and cleaner manufacturing. The mining sector, contributing a substantial 13.6% to Australia's GDP in 2023, is increasingly adopting VSDs to enhance energy efficiency and operational effectiveness. Concurrently, construction and manufacturing industries are projected to drive demand for VSD technologies, favoring precise motor speed control in applications such as HVAC, water treatment, and conveyor systems. Market Segmentation by Type: By 2031, DC drives are expected to lead in revenue growth due to their efficiency and applications requiring precise speed and torque control, such as industrial machinery. The AC drive segment maintains the largest market share, driven by advances in energy efficiency and seamless integration into renewable energy systems, underlining their importance in highly automated industries. Market Segmentation by Voltage: Low-voltage VSDs are projected to dominate in revenue and volume due to their affordability and versatility across smaller industries and residential applications, where they enhance energy efficiency significantly. Meanwhile, medium-voltage VSDs are expected to witness the highest growth rates, buoyed by increasing adoption in large-scale industrial applications. Market Segmentation by End-User: The industrial segment is poised to lead in revenue and growth by 2031, driven by automation and sustainability initiatives across manufacturing, mining, and infrastructure sectors. The automotive segment ranks second in growth, spurred by rising EV production and adoption in Australia. Market Segmentation by Application: The HVAC sector is predicted to exhibit the highest revenue growth rate, underpinned by the demand for energy-efficient, smart building technologies and stringent environmental regulations. Conversely, compressors are set to account for the largest revenue share, integral to processes in manufacturing, food & beverage, and oil & gas industries. Key Attractiveness of the Report: 10-Year Market Numbers. Historical Data from 2021 to 2024, with a Base Year of 2024. Forecast extending to 2031. Key Performance Indicators impacting the market. Major upcoming developments and projects. Key Highlights: Australia VSD Market Overview and Outlook. Forecast for Market Revenues and Volume from 2021 to 2031. Detailed analyses by Type, Voltage, End-User, and Application. Market Drivers and Restraints, Industry Life Cycle, and Porter's Five Forces Analysis. Competitive Benchmarking and Company Profiles. Strategic Recommendations. Company Profiles Schneider Electric SE ABB Ltd Siemens AG Danfoss A/S WEG S.A. Hitachi Ltd. Omron Corporation Toshiba International Corporation Pty Ltd. Eaton Corporation plc Invertek Drives Ltd. Robert Bosch (Australia) Pty Ltd Darwin Motion PTY. LTD For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Engadget
19-05-2025
- Engadget
Elgato's Stream Deck breaks free from the company's hardware
The Elgato Stream Deck is expanding into a hardware-agnostic platform. On Monday, the company unveiled a software version of the programmable shortcut device. Also on tap are a module for integration in third-party products and DIY projects, an Ethernet dock and an updated Stream Deck MK.2 with scissor-switch keys. There's a new version of the popular Stream Deck MK.2. The only difference is that this version ditches membrane keys in favor of scissor-switch ones. Scissor keys (found on many laptops, like modern MacBooks) have a shorter travel distance and sharper actuation than the mushy-feeling ones on the (still available) legacy MK.2. The Stream Deck MK.2 Scissor Keys costs $150. Shipments begin around the beginning of June. Virtual Stream Deck (VSD) is a software-only counterpart of the classic devices. Like the hardware versions, the VSD includes a familiar grid of programmable shortcut buttons. Anything you'd configure for a device like the Stream Deck MK.2 or XL, you can also do for the VSD. Place the interface anywhere on your desktop, pin it for quick access or trigger it with a mouse click or hotkey. Presumably to avoid cannibalizing its hardware business, Elgato is limiting the VSD to owners of its devices. Initially, it will only be available to people who have Stream Deck hardware or select Corsair peripherals (the Xeneon Edge and Scimitar Elite WE SE Mouse). The company says the VSD will soon be rolled out to owners of additional devices. The VSD has one frustrating requirement. It only works when one of those compatible accessories is connected to your computer. Unfortunately, that means you can't use it as a virtual Stream Deck replacement, mirroring your shortcuts while you and your laptop are on the go. That seems like a missed opportunity. Instead, it's more like a complement to Stream Deck hardware while it's connected — a way to get more shortcuts than the accessory supports. It's also a method for Corsair accessory owners to get Stream Deck functionality without buying one. Regardless, Virtual Stream Deck launches with the Stream Deck 7.0 beta software. Stream Deck Modules can be built into hardware not made by Elgato. So, hobbyists, startups and manufacturers can incorporate the OLED shortcut buttons into their DIY projects or products. The only difference is their more flexible nature. Otherwise, they function the same as legacy Stream Deck products. Stream Deck Modules have an aluminum chassis that's "ready to drop straight into a custom mount, machine or product." They're available in six-, 15- and 32-key variants. The modules begin shipping today. You'll pay $50 for the six-key version, $130 for the 15-key one and $200 for the 32-key variant. (If you're providing them for an organization, Elgato offers volume discounts.) The Elgato Network Dock gives Stream Deck devices their own Ethernet connections. This untethers the shortcuts from the desktop, allowing for "custom installations, remote stations and more." The Network Dock supports both Power over Ethernet (PoE) and non-PoE networks. You can set up its IP configuration on-device. The dock costs $80 and ships in August.
Yahoo
01-05-2025
- Health
- Yahoo
RFK Jr to require all new vaccines to undergo placebo testing
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is requiring all new vaccines to undergo placebo-controlled trials in a policy change the agency described as a "radical departure from past practices." "Under Secretary Kennedy's leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to licensure — a radical departure from past practices," an HHS spokesperson said to Fox News Digital on Thursday. HHS suggested that childhood-recommended vaccines listed under the Center for Disease Control and Prevention, for instance, should be tested. "Except for the COVID vaccine, none of the vaccines on the CDC's childhood recommended schedule was tested against an inert placebo, meaning we know very little about the actual risk profiles of these products," the HHS spokesperson said. Robert F. Kennedy Jr: Measles Outbreak Is A Call To Action For All Of Us Placebo testing, which involves volunteers receiving dummy injections such as saline shots, is already a common practice for new pathogens. Updated versions of proven protective immunizations, however, often do not undergo new placebo trials and are instead tested against existing vaccines. Read On The Fox News App Some health experts have raised concerns about conducting placebo trials, arguing that such tests could expose people to illnesses that otherwise could have been prevented. "Vaccine trial design can raise challenging ethical questions, especially regarding the use of placebo controls when an efficacious vaccine exists," a 2014 World Health Organization report published on the National Institutes of Health's website says. The risks of using a placebo control may be ethically justified even when an efficacious vaccine exists if the trial is "in settings where vaccine supplies are limited, where vaccines remain investigational and/or where public health recommendations for use of these vaccines have not been made," according to an article from the European Society of Clinical Microbiology and Infectious Diseases, also on the NIH website, citing a trial from a pharmaceutical company. Watch Full Interview With Dr. Marc Siegel And Rfk Jr. On Fox Nation HHS also claimed that the CDC has not been monitoring vaccine complications adequately, and criticized its current surveillance system. "The CDC's former practice of suppressing information about vaccine injuries has badly eroded trust in our public health agencies," the agency said. "The CDC's own research has shown that the post-licensure surveillance system, VAERS, captures fewer than 1% of vaccine injuries," the HHS spokesperson said. "It's a system that was designed to fail. The Vaccine Safety Datalink (VSD) — intended as a backup to VAERS — is virtually unusable for serious research. Both systems have become templates of regulatory malpractice." Kennedy, who has repeatedly said vaccines are not adequately tested for safety, is calling for greater transparency in its testing and approval process. "Secretary Kennedy's HHS has pledged radical transparency to the American public," the spokesperson said. "This means being honest and straightforward about what we know — and what we don't know — about medical products, including vaccines." "HHS is now building surveillance systems that will accurately measure vaccine risks as well as benefits — because real science demands both transparency and accountability," the spokesperson article source: RFK Jr to require all new vaccines to undergo placebo testing
Fox News
01-05-2025
- Health
- Fox News
RFK Jr to require all new vaccines to undergo placebo testing
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is requiring all new vaccines to undergo placebo-controlled trials in a policy change the agency described as a "radical departure from past practices." "Under Secretary Kennedy's leadership, all new vaccines will undergo safety testing in placebo-controlled trials prior to licensure — a radical departure from past practices," an HHS spokesperson said to Fox News Digital on Thursday. HHS suggested that childhood-recommended vaccines listed under the Center for Disease Control and Prevention, for instance, should be tested. "Except for the COVID vaccine, none of the vaccines on the CDC's childhood recommended schedule was tested against an inert placebo, meaning we know very little about the actual risk profiles of these products," the HHS spokesperson said. Placebo testing, which involves volunteers receiving dummy injections such as saline shots, is already a common practice for new pathogens. Updated versions of proven protective immunizations, however, often do not undergo new placebo trials and are instead tested against existing vaccines. Some health experts have raised concerns about conducting placebo trials, arguing that such tests could expose people to illnesses that otherwise could have been prevented. "Vaccine trial design can raise challenging ethical questions, especially regarding the use of placebo controls when an efficacious vaccine exists," a 2014 World Health Organization report published on the National Institutes of Health's website says. The risks of using a placebo control may be ethically justified even when an efficacious vaccine exists if the trial is "in settings where vaccine supplies are limited, where vaccines remain investigational and/or where public health recommendations for use of these vaccines have not been made," according to an article from the European Society of Clinical Microbiology and Infectious Diseases, also on the NIH website, citing a trial from a pharmaceutical company. HHS also claimed that the CDC has not been monitoring vaccine complications adequately, and criticized its current surveillance system. "The CDC's former practice of suppressing information about vaccine injuries has badly eroded trust in our public health agencies," the agency said. "The CDC's own research has shown that the post-licensure surveillance system, VAERS, captures fewer than 1% of vaccine injuries," the HHS spokesperson said. "It's a system that was designed to fail. The Vaccine Safety Datalink (VSD) — intended as a backup to VAERS — is virtually unusable for serious research. Both systems have become templates of regulatory malpractice." Kennedy, who has repeatedly said vaccines are not adequately tested for safety, is calling for greater transparency in its testing and approval process. "Secretary Kennedy's HHS has pledged radical transparency to the American public," the spokesperson said. "This means being honest and straightforward about what we know — and what we don't know — about medical products, including vaccines." "HHS is now building surveillance systems that will accurately measure vaccine risks as well as benefits — because real science demands both transparency and accountability," the spokesperson added.
Yahoo
30-04-2025
- Health
- Yahoo
The little-known database at the heart of Kennedy's vaccine conspiracy theory
For as long as Robert F. Kennedy Jr. has falsely claimed that vaccines cause widespread harm — from autism to sudden death — he has pointed to the one source he says could immediately prove it. In speeches, interviews and writings, Kennedy has repeatedly claimed that the evidence of a massive public health cover-up lies buried in a little-known database of medical records of some 12 million Americans: the Vaccine Safety Datalink, or VSD. 'For decades, the CDC has kept a tight grip on the Vaccine Safety Datalink, concealing vital vaccine safety information from the public,' Kennedy said in 2023. Kennedy now oversees the Centers for Disease Control and Prevention — including the Vaccine Safety Datalink — and one of his first initiatives as health secretary was to launch his long-dreamed-of study using the VSD to investigate the link between childhood vaccines and autism. It's a theory that has already been disproven in dozens of studies, many using VSD data. 'We're going to be able to get into these databases and give answers to the American public,' Kennedy said last month. He told President Donald Trump at recent Cabinet meeting that he would reveal the cause of autism by September. However, in recent weeks, Kennedy's anti-vaccine allies have begun casting doubt on this pledge, once again alleging a government conspiracy to block access to the truth. Without evidence, anti-vaccine lawyer Aaron Siri and activist Del Bigtree have claimed on the internet show "The HighWire" that the CDC scattered the vaccine safety data after Kennedy took office, making it unavailable for Kennedy's team to examine. The goal, according to Siri, was to 'thwart the ability for the current administration to actually conduct a study in the VSD.' It's a pattern that has echoed through the first months of the Trump administration: Onetime outsiders who had long asserted that the federal government was hiding the truth suddenly had access to all the government documents they could want — only to reveal that, perhaps, there were no nefarious secrets after all. The JFK assassination files exposed little about his killing that wasn't already known. The release of records in the Jeffrey Epstein sex trafficking case was a dud. Trump and Elon Musk's claims that millions of people over 100 were receiving Social Security quickly fell apart. Now, it appears that anti-vaccine activists are similarly girding for the possibility that Kennedy's promises may fall short — and they're already laying the groundwork for someone to blame. 'We've been saying that database is where the answers are,' Bigtree, who was communications director for Kennedy's 2024 presidential campaign, said of the VSD on 'The HighWire' last week. 'You could do the study in probably minutes with AI and computer learning and everything that's possible. Then the moment before Bobby gets in there to be able to do that study, what did they do? They obliterated it.' It's not clear exactly what Bigtree and Siri meant; neither responded to requests for comment. Kennedy also didn't respond. A spokesperson for the Department of Health and Human Services initially said he would 'look into it,' but did not respond to further requests for comment. A CDC spokesperson confirmed that nothing about the stewardship of VSD data had changed in the last year. There's one thing that Bigtree and Siri have right: The data in the VSD is not actually housed at the CDC — but that's not a recent change. The VSD is a collaboration between a small team at the CDC's Immunization Safety Office and 11 private health care organizations. Since the 1990s, it's been used to monitor vaccine safety and conduct studies of rare side effects. 'These studies that use the VSD are able to tell the difference between a condition that coincidentally happens after vaccination and a condition that may actually be the result of vaccination,' said Dr. Joshua Sharfstein, vice dean for public health practice at the Johns Hopkins Bloomberg School of Public Health. The health care organizations used to send their anonymized medical data to the CDC each year for analysis, but since 2001, the organizations have kept the data on their own servers, to ensure it stays secure. 'Sometimes people have the image that if there's a vaccine safety study, there must be one giant database with all the information in it,' Sharfstein said. 'If you're not familiar with how distributed networks of data are designed and used in studies, then it can be confusing. Because there is no one big dataset. There is no single file that can just be sent or released.' The conspiracy lore around the VSD began in the early aughts, around the time that Kennedy, then an environmental lawyer, was being introduced to the anti-vaccine movement. At that point, the only groups with access to the VSD were the CDC and the participating health care organizations. The studies they produced relied on the data they collected, including from doctor and hospital visits, vaccinations, pharmacies and lab results. Then in 2002, Rep. Dan Burton, R-Ind., who had a grandson he believed had been injured by vaccines, allied with several parent-led autism groups. Frustrated with anti-vaccine researchers' lack of access to data that might prove the link, Burton threatened to subpoena the VSD's patient records. At a hearing on the topic, Rep. Henry Waxman, D-Calif., urged Burton not to do it. 'A subpoena could have the effect of driving HMOs from the program and destroying CDC's ability to scientifically test hypotheses relating to adverse events potentially associated with vaccines,' Waxman warned, referring to the health care organizations. (Burton and Waxman left Congress in the mid-2010s.) Subpoenaing millions of medical records 'would have been a profound invasion of privacy,' said Johns Hopkins' Sharfstein. The CDC offered a solution: It would work with the participating health organizations to get independent researchers access to the data. Among the earliest beneficiaries — with the help of former Rep. Dave Weldon, R-Fla., the recently withdrawn CDC director nominee — were the anti-vaccine researchers Mark and David Geier, a father-son pair who baselessly theorized that autism was the result of an interaction between a preservative in vaccines and testosterone. (Mark Geier died this year in Florida, over a decade after being stripped of his medical license in several states, partly for improperly treating autistic children with hormone blockers. David Geier, who was disciplined by the Maryland Board of Physicians for practicing medicine without a license in 2012, was hired at HHS this year as a senior data analyst to reanalyze vaccine safety data under Kennedy, according to two sources familiar with the plan.) The Geiers' work with VSD data was marked by alleged ethical breaches. In 2003 and 2004, the Geiers visited the CDC's Maryland data center to access VSD data for a study looking at whether the diphtheria, tetanus and pertussis vaccine increased risks for harmful side effects. Instead, according to a letter of complaint from one of the health care groups, Kaiser Permanente Northern California, the Geiers violated protocol and began comparing rates of autism in children who received vaccines with different amounts of a preservative. Further, Kaiser Permanente said the Geiers tried to merge datasets in a way that would have risked patients' confidentiality, then tried to remove files from the datacenter. Subsequently, Kaiser Permanente suspended the Geiers' access to the VSD. The Geiers denied the accusations and published their findings in journals known more for conspiracy theories than rigorous science. At an Institute of Medicine panel in 2004, Mark Geier claimed the VSD data they analyzed showed that vaccines were linked to autism. Their published papers have been widely criticized by scientists and their findings never replicated or supported by mainstream research. In 2006, they were approved for another study using VSD data, and again, stopped after violating protocol, according to lawyers representing the government in a set of test cases known as the Omnibus Autism Proceedings. Lawyers representing the parents of autistic children — for whom the Geiers had been providing research — suggested in legal filings that the Geiers had been unfairly banned at the whims of CDC. For the Geiers, the experience was one of oppression. At anti-vaccine conferences, they presented PowerPoints alleging that the CDC had 'restricted' their access to data and 'attacked' their findings. At the same conferences, Kennedy, who has consistently praised the Geiers, told a similar story. 'Oh, they've hidden it, and they won't let anybody in it, except their own guys who cherry-pick and design these fabricated studies and change the protocols constantly to try to use it to defend vaccines,' Kennedy said in a 2017 keynote at AutismOne, an anti-vaccine conference for parents of autistic children where the Geiers also presented. 'It's being used instead to craft these fabricated, fraudulent studies,' he said, 'to fool the public about vaccine safety.' That same year, as Trump considered chairing a committee to review vaccine safety, Kennedy and a group of anti-vaccine activists met with Francis Collins, then the director of the National Institutes of Health, to ask him to 'open up' the VSD to scientists who would 'investigate whether vaccines are associated with the epidemic of health disorders plaguing our children today.' In a letter following the meeting, Collins, who resigned from the NIH last month, told Kennedy that because of privacy concerns, access was limited to researchers who made formal requests and met certain criteria. Further, Collins said the kind of study Kennedy had suggested would be difficult because the sample population of unvaccinated children in the VSD — already just a fraction of the U.S. population — would be too small. Now, with Kennedy at the helm of HHS and Geier working for him, there are no roadblocks left. This article was originally published on
